<DOC>
	<DOCNO>NCT02068794</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose oncolytic measles virus encode thyroidal sodium iodide symporter ( MV-NIS ) infect mesenchymal stem cell see well work treat patient ovarian cancer come back . Mesenchymal stem cell may able carry tumor-killing substance directly ovarian cancer cell .</brief_summary>
	<brief_title>MV-NIS Infected Mesenchymal Stem Cells Treating Patients With Recurrent Ovarian Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximally tolerate dose ( MTD ) intraperitoneal administration Edmonston 's strain measles virus genetically engineer produce sodium iodine symporter ( NIS ) ( measles virus [ MV ] -NIS ) patient recurrent ovarian cancer , deliver adipose tissue derive mesenchymal stem cell ( MSC ) . ( Phase I ) II . To assess 4 month progression free survival patient treat regimen . ( Phase II ) SECONDARY OBJECTIVES : I . To assess tolerability regimen . ( Phase II ) II . To assess response rate , progression-free survival , overall survival patient treat regimen . ( Phase II ) TERTIARY OBJECTIVES : I . To assess time course viral gene expression virus elimination biodistribution virally infected cell various time point infection MV-NIS versus MSC deliver MV-NIS use single-photon emission compute tomography ( SPECT ) /computed tomography ( CT ) imaging . ( Phase II ) II . To assess viremia , viral replication , measles virus shedding/persistence follow intraperitoneal administration . ( Phase II ) III . To assess humoral cellular immune response inject virus . ( Phase II ) IV . To assess preliminary fashion development antitumor immune response . ( Phase II ) OUTLINE : This phase I , dose-escalation study follow phase II study . Patients receive oncolytic measles virus encode thyroidal sodium iodide symporter intraperitoneally ( IP ) 30 minute day 1 course 1 MV-NIS infect mesenchymal stem cell IP 30 minute subsequent course . Treatment repeat every 28 day 5 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 month 5 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Carcinoma , Endometrioid</mesh_term>
	<mesh_term>Cystadenocarcinoma , Serous</mesh_term>
	<mesh_term>Adenocarcinoma , Mucinous</mesh_term>
	<mesh_term>Cystadenocarcinoma</mesh_term>
	<mesh_term>Brenner Tumor</mesh_term>
	<mesh_term>Adenocarcinoma , Clear Cell</mesh_term>
	<criteria>Must : Recurrent progressive ovarian cancer primary peritoneal cancer prior treatment platinum taxanes Histologic confirmation original primary tumor Prior bilateral oophorectomy The following histologic epithelial cell type eligible : serous adenocarcinoma , endometrioid adenocarcinoma , mucinous adenocarcinoma , undifferentiated carcinoma , clear cell adenocarcinoma , mixed epithelial carcinoma , transitional cell carcinoma , malignant Brenner 's tumor , adenocarcinoma otherwise specify ( NOS ) Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 , 2 Absolute neutrophil count ( ANC ) &gt; = 1500/uL Platelet ( PLT ) &gt; = 100,000/uL Total bilirubin = &lt; upper normal limit Aspartate aminotransferase ( AST ) = &lt; 2 x upper limit normal ( ULN ) Creatinine = &lt; 1.5 x ULN Hemoglobin ( Hgb ) &gt; = 9.0 g/dL Normal cardiac function define normal ejection fraction multi gate acquisition scan ( MUGA ) echocardiogram Normal oxygen saturation baseline ABG ( arterial blood gas ) test The following pulmonary function test ( PFT ) value baseline : Forced expiratory volume one second ( FEV1 ) &gt; 80 % predict FEV1/forced vital capacity ( FVC ) &gt; 80 % Residual volume ( RV ) /total lung capacity ( TLV ) &gt; = 80 % Provide inform write consent Willing return Mayo Clinic Rochester followup Life expectancy &gt; = 12 week Willing provide biologic specimen require protocol Measurable disease exam CT scan , patient cancer antigen ( CA ) 125 elevation microscopic residual without measurable disease imaging , willingness undergo laparoscopy evaluation treatment effect radiographic progression 6 treatment cycle Cluster differentiation ( CD ) 4 count &gt; = 200/uL &gt; = 15 % peripheral blood lymphocytes Epithelial tumor low malignant potential , stromal tumor , germ cell tumor ovary Known standard therapy patient 's disease potentially curative definitely capable extend life expectancy ; subject exclude first relapse recur &gt; 6 month completion primary ( adjuvant ) chemotherapy Active infection = &lt; 5 day prior registration History tuberculosis history tuberculosis skin test ( PPD ) positivity History malignancy = &lt; 5 year prior registration except nonmelanoma skin cancer , carcinoma situ cervix , ductal carcinoma situ ( DCIS ) Any follow prior therapy : Chemotherapy = &lt; 3 week prior registration Immunotherapy = &lt; 4 week prior registration Biologic therapy = &lt; 4 week prior registration Extensive abdominal surgery include enterotomy ( y ) = &lt; 3 week prior registration ; criterion apply placement peritoneal PortACath lysis adhesion time registration Any viral gene therapy prior registration Radiation therapy abdomen pelvis New York Heart Association classification III IV , know symptomatic coronary artery disease , symptom coronary artery disease system review , know cardiac arrhythmia ( atrial fibrillation supraventricular tachycardia [ SVT ] ) Other cardiac pulmonary disease , investigator discretion , impair treatment safety Requiring blood product support Central nervous system ( CNS ) metastases seizure disorder Human immunodeficiency virus ( HIV ) positive test result history immunodeficiency History organ transplantation History chronic hepatitis B C Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( utilized nonFood Drug Administration [ FDA ] approve indication context research investigation ) Intraabdominal disease &gt; 8 cm diameter time registration , intrahepatic disease , disease beyond abdominal cavity ; patient intraabdominal lymph node involvement eligible base biodistribution data indicate viral dissemination lymph node follow intraperitoneal administration Treatment oral/systemic corticosteroid , exception topical inhaled steroid Exposure household contact = &lt; 15 month old household contact know immunodeficiency Allergy measles vaccine history severe reaction prior measles vaccination Allergy iodine ; include reaction intravenous contrast material Any pathology condition principle investigator may deem negatively impact treatment safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>